JP2017511129A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511129A5 JP2017511129A5 JP2016559160A JP2016559160A JP2017511129A5 JP 2017511129 A5 JP2017511129 A5 JP 2017511129A5 JP 2016559160 A JP2016559160 A JP 2016559160A JP 2016559160 A JP2016559160 A JP 2016559160A JP 2017511129 A5 JP2017511129 A5 JP 2017511129A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- residue
- polypeptide
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 249
- 229920001184 polypeptide Polymers 0.000 claims description 174
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 174
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 174
- 238000000034 method Methods 0.000 claims description 139
- 238000006467 substitution reaction Methods 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 38
- 102220055516 rs76646066 Human genes 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 108091006515 Anion channels Proteins 0.000 claims description 16
- 102000037829 Anion channels Human genes 0.000 claims description 16
- 210000003169 central nervous system Anatomy 0.000 claims description 11
- 210000002569 neuron Anatomy 0.000 claims description 11
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000003259 recombinant expression Methods 0.000 claims description 9
- 210000003484 anatomy Anatomy 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 210000004126 nerve fiber Anatomy 0.000 claims description 6
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000003939 Membrane transport proteins Human genes 0.000 claims 2
- 108090000301 Membrane transport proteins Proteins 0.000 claims 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 2
- 230000009061 membrane transport Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000021194 SRP-dependent cotranslational protein targeting to membrane Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 101
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 73
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 73
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 73
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 52
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 52
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 52
- 239000004473 Threonine Substances 0.000 description 52
- 235000004279 alanine Nutrition 0.000 description 52
- 235000001014 amino acid Nutrition 0.000 description 52
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 52
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 39
- 125000000539 amino acid group Chemical group 0.000 description 39
- 102220064269 rs786205766 Human genes 0.000 description 13
- 102220582722 Heparan sulfate glucosamine 3-O-sulfotransferase 2_E90A_mutation Human genes 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972182P | 2014-03-28 | 2014-03-28 | |
| US61/972,182 | 2014-03-28 | ||
| PCT/US2015/023087 WO2015148974A2 (en) | 2014-03-28 | 2015-03-27 | Engineered light-activated anion channel proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017511129A JP2017511129A (ja) | 2017-04-20 |
| JP2017511129A5 true JP2017511129A5 (cg-RX-API-DMAC7.html) | 2018-05-10 |
Family
ID=54196574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559160A Ceased JP2017511129A (ja) | 2014-03-28 | 2015-03-27 | 遺伝子操作された光活性化アニオンチャネルタンパク質及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10052383B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3122761B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017511129A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106459138A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015237265A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2943367A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2725951T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015148974A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007024391A2 (en) | 2005-07-22 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US20090093403A1 (en) | 2007-03-01 | 2009-04-09 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| MX2010011657A (es) | 2008-04-23 | 2011-01-21 | Univ Leland Stanford Junior | Sistemas, metodos y composiciones para la estimulacion optica de celulas objetivo. |
| BRPI0915583A2 (pt) | 2008-06-17 | 2016-01-26 | Univ Leland Stanford Junior | aparelho e métodos para controle do desenvolvimento celular |
| WO2010006049A1 (en) | 2008-07-08 | 2010-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| CN106947741A (zh) | 2010-11-05 | 2017-07-14 | 斯坦福大学托管董事会 | 光活化嵌合视蛋白及其使用方法 |
| CA2816990A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| CA3036859A1 (en) | 2011-12-16 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| US20140024701A1 (en) | 2012-02-21 | 2014-01-23 | Circuit Therapeutics, Inc. | Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| KR102644929B1 (ko) | 2015-07-21 | 2024-03-08 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 자기 공명 영상 호환 가능한 광유전학을 위한 탄소 섬유 광단자 |
| JP2018529335A (ja) | 2015-09-15 | 2018-10-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 光応答性ポリペプチド及びその使用方法 |
| US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
| US10961296B2 (en) * | 2017-11-10 | 2021-03-30 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
| CN108192896B (zh) * | 2018-02-10 | 2021-05-07 | 中国烟草总公司郑州烟草研究院 | 一个烟草慢阴离子通道蛋白NtSLAH1及其应用 |
| WO2020061079A1 (en) * | 2018-09-18 | 2020-03-26 | California Institute Of Technology | Engineered light-sensitive proteins |
| WO2020059675A1 (ja) | 2018-09-20 | 2020-03-26 | 国立大学法人岩手大学 | 改変チャネルロドプシン |
| CN111263086A (zh) * | 2020-02-10 | 2020-06-09 | 江南大学 | 细胞融合的光电传感器的制作方法及其成像系统的工作方法 |
| US11921271B2 (en) | 2020-05-22 | 2024-03-05 | The Board Of Trustees Of The Leland Stanford Junior Univeristy | Multifocal macroscope for large field of view imaging of dynamic specimens |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| CA2085127C (en) | 1990-06-15 | 2002-12-10 | Barbara Cordell | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| AU758708B2 (en) | 1997-09-05 | 2003-03-27 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7632679B2 (en) | 2002-07-16 | 2009-12-15 | The Trustees Of Columbia University In The City Of New York | Systems and methods for screening for modulators of neural differentiation |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US20090093403A1 (en) | 2007-03-01 | 2009-04-09 | Feng Zhang | Systems, methods and compositions for optical stimulation of target cells |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2007024391A2 (en) | 2005-07-22 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated cation channel and uses thereof |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| ATE553206T1 (de) | 2006-08-24 | 2012-04-15 | Virovek Inc | Expression von genen mit überlappenden offenen leserastern in insektenzellen, verfahren und zusammensetzungen dafür |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US8401609B2 (en) | 2007-02-14 | 2013-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
| US8545543B2 (en) | 2009-10-08 | 2013-10-01 | Massachusetts Institute Of Technology | Methods and apparatus for microstructure lightguides |
| US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| WO2009119782A1 (ja) * | 2008-03-24 | 2009-10-01 | 国立大学法人東北大学 | 改変された光受容体チャネル型ロドプシンタンパク質 |
| MX2010011657A (es) | 2008-04-23 | 2011-01-21 | Univ Leland Stanford Junior | Sistemas, metodos y composiciones para la estimulacion optica de celulas objetivo. |
| MY152003A (en) | 2008-05-29 | 2014-08-15 | Univ Leland Stanford Junior | Cell line, system and method for optical control of secondary messengers |
| BRPI0915583A2 (pt) | 2008-06-17 | 2016-01-26 | Univ Leland Stanford Junior | aparelho e métodos para controle do desenvolvimento celular |
| SG191593A1 (en) | 2008-06-17 | 2013-07-31 | Univ Leland Stanford Junior | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
| WO2010006049A1 (en) | 2008-07-08 | 2010-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| NZ602416A (en) | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| ES2676274T3 (es) | 2010-03-17 | 2018-07-18 | The Board Of Trustees Of The Leland Stanford Junior University | Moléculas sensibles a la luz que permiten el paso de iones |
| CN106947741A (zh) | 2010-11-05 | 2017-07-14 | 斯坦福大学托管董事会 | 光活化嵌合视蛋白及其使用方法 |
| AU2011323197B2 (en) | 2010-11-05 | 2015-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of psychotic states |
| AU2011323237B2 (en) | 2010-11-05 | 2015-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optically-controlled CNS dysfunction |
| EP2635341B1 (en) | 2010-11-05 | 2018-08-08 | The Board of Trustees of the Leland Stanford Junior University | Upconversion of light for use in optogenetic methods |
| WO2012061681A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University. | Control and characterization of memory function |
| WO2012061688A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
| CA2816990A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized step function opsin proteins and methods of using the same |
| US8957028B2 (en) | 2010-11-13 | 2015-02-17 | Massachusetts Institute Of Technology | Red-shifted opsin molecules and uses thereof |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| CA3036859A1 (en) | 2011-12-16 | 2013-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| US20140024701A1 (en) | 2012-02-21 | 2014-01-23 | Circuit Therapeutics, Inc. | Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor |
| CN104270942B (zh) | 2012-03-20 | 2018-02-02 | 斯坦福大学托管董事会 | 非人类动物抑郁症模型及其使用方法 |
| EP3659518A1 (en) | 2012-11-21 | 2020-06-03 | Circuit Therapeutics, Inc. | System and method for optogenetic therapy |
| CA2906756A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
| US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
| EP2991491B1 (en) | 2013-04-29 | 2019-12-25 | The Board of Trustees of the Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
| CN105829538A (zh) | 2013-08-14 | 2016-08-03 | 小利兰·斯坦福大学托管委员会 | 用于控制疼痛的组合物和方法 |
-
2015
- 2015-03-27 JP JP2016559160A patent/JP2017511129A/ja not_active Ceased
- 2015-03-27 US US15/126,859 patent/US10052383B2/en active Active
- 2015-03-27 WO PCT/US2015/023087 patent/WO2015148974A2/en not_active Ceased
- 2015-03-27 CA CA2943367A patent/CA2943367A1/en not_active Abandoned
- 2015-03-27 ES ES15770114T patent/ES2725951T3/es active Active
- 2015-03-27 EP EP15770114.5A patent/EP3122761B1/en not_active Not-in-force
- 2015-03-27 CN CN201580028022.1A patent/CN106459138A/zh active Pending
- 2015-03-27 EP EP19156461.6A patent/EP3581580A1/en not_active Withdrawn
- 2015-03-27 AU AU2015237265A patent/AU2015237265A1/en not_active Abandoned
-
2018
- 2018-08-07 US US16/057,639 patent/US10478499B2/en active Active
-
2019
- 2019-10-11 US US16/600,076 patent/US20200030446A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511129A5 (cg-RX-API-DMAC7.html) | ||
| JP2016518840A5 (cg-RX-API-DMAC7.html) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| PH12022550232A1 (en) | Gipr-agonist compounds. | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
| ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| EP2189471A4 (en) | FOXM1 PEPTIDE AND MEDICAMENT THEREFOR | |
| AU2003242305A8 (en) | Hla-a24-restricted cancer antigen peptide | |
| JP2014510519A5 (cg-RX-API-DMAC7.html) | ||
| ES2925550T3 (es) | Trastornos neurodegenerativos | |
| EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
| BR112015001028A2 (pt) | antagonistas de receptor 5-ht3 | |
| MX2018015461A (es) | Genes cln1 optimizados y cassettes de expresion y su uso. | |
| PH12022551223A1 (en) | Adenosine receptor antagonist compounds | |
| DK2407536T3 (da) | Adp-ribosyltransferase-fusionsvariantproteiner | |
| JP2018506287A5 (cg-RX-API-DMAC7.html) | ||
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| JP2017506889A (ja) | 青色光活性化イオンチャネル分子およびその使用 | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| EA202090802A1 (ru) | Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью | |
| ATE501256T1 (de) | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung | |
| MX2021010132A (es) | Peptido con accion selectiva hacia receptores gip y glp-2 para el tratamiento contra trastornos oseos. |